Full video transcriptClick to expand
Auto-generated transcript of @dr.labrasca's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00If you're on a GLP1 like Ozempic,
- 0:01would go via Monjara, et cetera.
- 0:03I stopped it two weeks before it's humming talk
- 0:04to reduce the anesthesia risk from delayed stomach emptying.
- 0:07And we restarted the day after surgery
- 0:09as long as you're tolerating fluids and food.
- 0:11Coordinate with your prescribing doc,
- 0:12and if you're very nauseous post-op,
- 0:13wait a day or two before restarting, that's it.
GLP-1 drugs and tummy tucks: what the surgery timing data shows
Quick answer
GLP-1 receptor agonists slow gastric emptying in a dose-dependent manner, raising the risk of pulmonary aspiration under general anesthesia even in patients who have fasted per standard guidelines. The creator recommends a two-week pre-operative hold for all GLP-1 medications before abdominoplasty, with same-day or next-day restart contingent on post-operative tolerance of fluids and food. This protocol aligns broadly with ASA 2023 interim guidance, though that guidance is based on limited evidence and recommends individualized clinical judgment rather than a fixed hold duration.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 drugs and tummy tucks: what the surgery timing data shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
GLP-1 drugs and tummy tucks: what the surgery timing data shows is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "GLP-1 drugs and tummy tucks: what the surgery timing data shows" from Dr. LaBrasca Plastic Surgery. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists slow gastric emptying in a dose-dependent manner, raising the risk of pulmonary aspiration under general anesthesia even in patients who have fasted per standard guidelines.
The reason this review is not generic is the source wording and the canonical claim label "glp1 glp 1 and still wanting a tummy tuck here s what you need to." In this clip, the useful excerpt is: "If you're on a GLP1 like Ozempic, would go via Monjara, et cetera." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
GLP-1 receptor agonists slow gastric emptying in a dose-dependent manner, raising the risk of pulmonary aspiration under general anesthesia even in patients who have fasted per standard guidelines.
FormBlends verdict
GLP-1 social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- GLP-1 receptor agonists slow gastric emptying in a dose-dependent manner, raising the risk of pulmonary aspiration under general anesthesia even in patients who have fasted per standard guidelines. The creator recommends a two-week pre-operative hold for all GLP-1 medications before abdominoplasty, with same-day or next-day restart contingent on post-operative tolerance of fluids and food. This protocol aligns broadly with ASA 2023 interim guidance, though that guidance is based on limited evidence and recommends individualized clinical judgment rather than a fixed hold duration.
- The ASA issued interim 2023 guidance on GLP-1 perioperative management, recommending at minimum skipping the last weekly dose before surgery, but acknowledged the evidence is limited and no universal hold duration has been established.
- Semaglutide has a half-life of roughly 7 days, meaning two weeks represents approximately two half-lives, not full pharmacokinetic clearance, though clinical effects on gastric motility likely resolve before complete drug elimination.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- The ASA issued interim 2023 guidance on GLP-1 perioperative management, recommending at minimum skipping the last weekly dose before surgery, but acknowledged the evidence is limited and no universal hold duration has been established.
- Semaglutide has a half-life of roughly 7 days, meaning two weeks represents approximately two half-lives, not full pharmacokinetic clearance, though clinical effects on gastric motility likely resolve before complete drug elimination.
- Grover et al. (2023, Obesity Surgery) documented that higher doses of semaglutide produce more pronounced gastric emptying delays than lower doses, meaning a flat two-week rule does not account for dose variation.
- Hamilton et al. (2024, Anesthesiology) reviewed perioperative GLP-1 protocols and found wide institutional variation, with hold times ranging from 24 hours to 6 weeks depending on the drug and clinical judgment.
- Post-operative nausea and vomiting after abdominoplasty is already common without GLP-1 use, and reintroducing a drug with known GI side effects on day one post-op carries real patient comfort and safety considerations that are not yet settled by clinical trial data.
- Patients should ensure their surgeon and GLP-1 prescriber are actively communicating, not assuming the other has addressed the perioperative plan.
- No randomized controlled trial as of mid-2024 has specifically examined optimal GLP-1 hold and restart timing around elective cosmetic procedures, meaning all current protocols are expert opinion or observational in origin.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @dr.labrasca actually say?
The creator, who appears to be a plastic surgeon, gave a quick protocol for GLP-1 users heading into abdominoplasty: stop the medication two weeks before surgery to lower anesthesia risk from delayed gastric emptying, then restart the day after surgery if the patient is tolerating food and fluids. If nausea is bad post-op, wait another day or two. That is essentially the whole recommendation.
This is a narrow, procedural clip, not a deep dive into the pharmacology. The creator frames it as a checklist item, not a clinical debate. The advice to "coordinate with your prescribing doc" is the right call, even if it gets buried at the end of a 30-second video.
Does the science back this up?
Mostly, yes, though the two-week figure is the contested part. The risk being referenced is real: GLP-1 receptor agonists slow gastric emptying, which raises aspiration risk under general anesthesia even in fasted patients. This is not hypothetical. Case reports and retrospective data have documented residual gastric contents in patients who fasted per standard guidelines.
The American Society of Anesthesiologists issued guidance in 2023 recommending a longer hold for weekly injectables like semaglutide, specifically suggesting the last dose be skipped before surgery, which for a weekly drug translates to roughly one week at minimum. Some anesthesiologists argue for longer holds based on semaglutide's half-life of approximately one week, meaning full clearance takes closer to five half-lives, or five weeks, though clinical effect on motility likely resolves faster than full pharmacokinetic clearance. Liraglutide, a daily drug, is a different story. The two-week figure for weekly semaglutide is defensible but not uniformly agreed upon. Hamilton et al. (2024, Anesthesiology) noted the evidence base is still thin and protocols vary widely by institution.
What did they get wrong (or right)?
The creator gets credit for flagging the aspiration risk at all. Many practitioners still are not communicating this to patients. The restarting advice, "as long as you're tolerating fluids and food," is reasonable and consistent with common post-op management.
What is imprecise: the two-week hold is stated as settled fact when it is not. The ASA's 2023 guidance acknowledged the evidence is limited and that practitioners should use clinical judgment. Two weeks may be adequate for liraglutide or tirzepatide at lower doses, but for high-dose weekly semaglutide it may not be sufficient in every patient. The creator also bundles "Ozempic, Mounjaro, et cetera" without distinguishing between daily and weekly formulations, or between doses, which have meaningfully different gastric emptying effects. Grover et al. (2023, Obesity Surgery) documented that higher semaglutide doses produced more pronounced delays in gastric emptying than lower doses, making a flat two-week rule for all GLP-1s an oversimplification.
What should you actually know?
If you are on a GLP-1 and planning any surgery requiring general anesthesia, this conversation needs to happen between your surgeon and your prescriber, not just one of them. The two-week hold is a reasonable starting point but should not be treated as a universal rule. Your specific drug, dose, duration of use, and individual gastric motility all matter.
The post-op restart question is genuinely underexplored. Restarting the day after a tummy tuck may be appropriate for some patients, but nausea is already common after abdominoplasty without GLP-1 reintroduction. Adding a drug that frequently causes nausea and vomiting to a post-operative gut that is already stressed is not trivial. The creator acknowledges this with the "wait a day or two" caveat, which is reasonable, but patients should know that some clinicians recommend a longer hold post-op as well. There is no randomized trial on this specific question as of mid-2024.
Bottom line
This is practical, directionally correct advice from someone who has clearly thought about this issue in a clinical setting. The gaps are in the nuance: not all GLP-1s are the same, not all doses carry the same risk, and the two-week figure has more uncertainty behind it than the confident delivery suggests. Patients should use this as a starting point for a real conversation, not a protocol to follow without verification.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Dr. LaBrasca Plastic Surgery · TikTok creator
19.0K views on this video
GLP-1 and still wanting a Tummy Tuck? Here's what you need to know! 💉 #glp1 #tummytuck #weightloss #plasticsurgery
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about the asa?
The ASA issued interim 2023 guidance on GLP-1 perioperative management, recommending at minimum skipping the last weekly dose before surgery, but acknowledged the evidence is limited and no universal hold duration has been established.
What does the video say about semaglutide has a half-life of roughly 7 days, meaning two?
Semaglutide has a half-life of roughly 7 days, meaning two weeks represents approximately two half-lives, not full pharmacokinetic clearance, though clinical effects on gastric motility likely resolve before complete drug elimination.
What does the video say about grover et al. (2023, obesity surgery) documented?
Grover et al. (2023, Obesity Surgery) documented that higher doses of semaglutide produce more pronounced gastric emptying delays than lower doses, meaning a flat two-week rule does not account for dose variation.
What does the video say about hamilton et al. (2024, anesthesiology) reviewed perioperative glp-1 protocols?
Hamilton et al. (2024, Anesthesiology) reviewed perioperative GLP-1 protocols and found wide institutional variation, with hold times ranging from 24 hours to 6 weeks depending on the drug and clinical judgment.
What does the video say about post-operative nausea?
Post-operative nausea and vomiting after abdominoplasty is already common without GLP-1 use, and reintroducing a drug with known GI side effects on day one post-op carries real patient comfort and safety considerations that are not yet settled by clinical trial data.
What does the video say about patients should ensure their surgeon?
Patients should ensure their surgeon and GLP-1 prescriber are actively communicating, not assuming the other has addressed the perioperative plan.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Dr. LaBrasca Plastic Surgery, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.